Head to head for first-timers
CoreAge Rx vs Longevixx
CoreAge Rx and Longevixx both offer GLP-1 telehealth, but they make different trade-offs on how gentle the start is, honest pricing, real support and access. Here they are side by side on the Mama-Match Score — our first-timer rubric.
CoreAge Rx
Higher scoreRank #31 for first-timers · Grade C
Mama-Match
Best for: Someone comparing dose prices who can obtain the offer, state availability and order terms in writing.
Visit CoreAge RxLongevixx
Rank #322 for first-timers · Grade C
Mama-Match
Best for: There is no honest answer, because the site settles almost nothing before you hand over your history.
Visit LongevixxThe verdict for a first step
CoreAge Rx edges out Longevixx on the Mama-Match Score, 73 to 28 (C vs C). Someone comparing dose prices who can obtain the offer, state availability and order terms in writing.
Longevixx is still a genuine option — "Plans from $129/mo · confirmed after provider review" is all the pricing there is: nothing by medication, nothing by dose, nothing fixed until after an assessment. On a single screen the homepage manages to say both "50-state telehealth" in a scrolling banner and "0 states telehealth access" in the stat block below it. And the headline figure, "~15–20% avg. body-weight change", is attributed to clinical trials of compounded semaglutide and tirzepatide. Those trials do not exist. Weigh the six first-timer factors below against your own priorities.
Side by side on all six factors
Both providers judged on the same first-timer rubric — the higher side on each factor is marked. See the methodology.
Price, access and features
| Detail | CoreAge Rx | Longevixx |
|---|---|---|
| Mama-Match Score | 73/100 · C | 28/100 · C |
| Overall rank | #31 | #322 |
| Semaglutide | $99/mo | From $129/mo, not confirmed until after provider review |
| Tirzepatide | $149/mo | No price of its own on the site |
| Coverage | Therapy-specific state restrictions; confirm eligibility | Contradicts itself on its own homepage: "0 states" beside "50-state telehealth" |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Mama-Match
CoreAge Rx
Rank #31 · Grade C
What we like
- Published prices for both molecules, with the same advertised amount at each dose
- The offer includes medication, consultation and shipping, without an advertised membership fee
- The legal footer identifies the platform and the entities responsible for clinical care
The caveats
- The main site and a separate offer page show different prices
- The FAQ and policy differ on automatic rebilling and denial refunds
- State restrictions; orders become final when sent to pharmacy, with a 30-day refund cutoff
Mama-Match
Longevixx
Rank #322 · Grade C
What we like
- "$0 if you're not approved" is said clearly, and said often
- Separates its programs by medication and by microdose rather than selling one vague plan
- Says the medication is compounded in the USA and shipped cold-chain, and carries the not-FDA-approved disclosure
The caveats
- The "~15–20% avg. body-weight change" figure is attributed to clinical trials of compounded semaglutide and tirzepatide: those trials do not exist, and those results come from studies of the brand-name drugs
- The only published price is "from $129/mo", confirmed after provider review, so nothing is fixed in advance
- Tirzepatide has its own program page but no price of its own
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Mama-Match Score. Prices, states and verification reflect what each provider disclosed publicly at our last review; the Mama-Match Score is our editorial judgment under the methodology. Prices change — confirm them on each provider’s site. Not medical advice; see our disclosure.
More head-to-heads
Keep comparing CoreAge Rx and Longevixx with the other providers we review for women.
Or browse the full comparison hub.